Welcome to our dedicated page for Janux Therapeutics news (Ticker: JANX), a resource for investors and traders seeking the latest updates and insights on Janux Therapeutics stock.
Janux Therapeutics, Inc. (NASDAQ: JANX) is a clinical-stage biopharmaceutical pioneer developing tumor-activated immunotherapies through its proprietary TRACTr and TRACIr platforms. This page serves as the definitive source for verified company announcements, offering stakeholders timely access to essential updates.
Key resources include: Press releases detailing clinical trial progress, regulatory milestones for novel cancer therapies, strategic partnerships in biopharmaceutical development, and financial disclosures. Our curated collection helps investors track innovations in bispecific T cell engagers and tumor microenvironment targeting.
Bookmark this page to monitor Janux's advancements in addressing immunotherapy challenges like systemic toxicity and tumor specificity. All content is sourced directly from official company communications, ensuring reliability for research and analysis needs.
Janux Therapeutics (NASDAQ: JANX) reported its Q4 and full year 2024 financial results, highlighting significant clinical progress and strong financial position. The company presented positive Phase 1 trial data for PSMA-TRACTr JANX007 in prostate cancer, showing impressive results including 100% PSA50 decline rates and 50% objective response rate in treated patients.
Financial highlights include $1.03 billion in cash and investments as of December 31, 2024, bolstered by a $402.5 million capital raise in December 2024. The company reported increased R&D expenses of $68.4 million and G&A expenses of $41.0 million for 2024, with a net loss of $69.0 million.
Clinical progress continues with ongoing enrollment for both JANX007 and JANX008 trials, with updates anticipated in 2025 along with an R&D Day to discuss new programs.
Janux Therapeutics (NASDAQ: JANX) has promoted Dr. Zachariah McIver to Chief Medical Officer. Dr. McIver, a physician-scientist with over 20 years of clinical research experience, previously served as Amgen's Executive Medical Director for more than 4 years, where he led BiTE assets development across multiple cancer types.
The company is developing immunotherapies through its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms. Their clinical pipeline includes JANX007, a TRACTr targeting PSMA in Phase 1 trials for mCRPC patients, and JANX008, a TRACTr targeting EGFR in Phase 1 trials for multiple solid cancers including colorectal, head and neck, lung, renal, and breast cancers.
Janux Therapeutics (NASDAQ: JANX) has successfully closed its previously announced public offering, raising $402.5 million in gross proceeds. The offering included 6,150,793 shares of common stock at $63.00 per share and 238,095 pre-funded warrants at $62.999 per warrant. The underwriters exercised their full option to purchase an additional 833,333 shares.
The offering was managed by several investment banks, including BofA Securities, TD Cowen, Stifel, Cantor, and William Blair as joint book-running managers. The company plans to use the proceeds to advance its clinical development pipeline and for general corporate purposes.
Janux Therapeutics (NASDAQ: JANX) has announced the pricing of a $350.0 million public offering, consisting of 5,317,460 shares of common stock at $63.00 per share and 238,095 pre-funded warrants at $62.999 per warrant. The company has granted underwriters a 30-day option to purchase up to 833,333 additional shares.
The offering, expected to close around December 6, 2024, is being managed by multiple investment banks including BofA Securities, TD Cowen, Stifel, Cantor, and William Blair as joint book-running managers. The proceeds will be used to advance clinical development of Janux's internal product pipeline and for general corporate purposes.
Janux Therapeutics (NASDAQ: JANX), a clinical-stage biopharmaceutical company, has announced a proposed public offering of $300.0 million of common stock shares or pre-funded warrants. The company plans to grant underwriters a 30-day option to purchase up to an additional $45.0 million of shares.
The offering will be managed by multiple joint book-running managers including BofA Securities, TD Cowen, Stifel, Cantor, and William Blair. Janux intends to use the proceeds to advance clinical development of its internal product pipeline and for general corporate purposes. The securities will be offered through a Registration Statement on Form S-3 filed with the SEC.
Janux Therapeutics (NASDAQ: JANX) announced positive interim clinical data for JANX007 in metastatic castration-resistant prostate cancer (mCRPC). In 16 heavily pre-treated patients, JANX007 showed remarkable efficacy with 100% achieving PSA50 declines, 63% reaching PSA90 declines, and 31% achieving PSA99 declines. The treatment demonstrated 50% objective response rate and was well-tolerated with primarily grade 1 and 2 side effects. Based on these results, Janux has selected doses for Phase 1b expansion trials targeting pre-PLUVICTO® 2L/3L patients, with another update expected in 2025.
Janux Therapeutics (NASDAQ: JANX) announced a virtual event scheduled for December 2, 2024, at 4:30 PM ET to discuss updated clinical data from JANX007's Phase 1a dose escalation trial in metastatic castration-resistant prostate cancer (mCRPC) patients. The company will also reveal doses selected for Phase 1b expansion studies. The event will feature CEO David Campbell and include a Q&A session. JANX007 is the company's first clinical TRACTr candidate targeting PSMA, while their second candidate, JANX008, targets EGFR for multiple solid cancers.
Janux Therapeutics reported Q3 2024 financial results and business updates. The company maintains $658.0 million in cash and investments, up from $344.0 million at end-2023. Q3 net loss widened to $28.1 million from $11.6 million year-over-year. R&D expenses increased to $18.6 million, while G&A expenses rose to $17.7 million. Patient enrollment continues for Phase 1 trials of JANX007 in prostate cancer and JANX008 in solid tumors. The company expects to provide JANX007 data updates and expansion cohort dose selection in 2024, with JANX008 updates anticipated in 2025.
Janux Therapeutics (Nasdaq: JANX) reported Q2 2024 financial results and business highlights. Key points include:
- Ongoing enrollment for PSMA-TRACTr (JANX007) in prostate cancer and EGFR-TRACTr (JANX008) in solid tumors
- Update on JANX007 data and expansion cohort doses expected in 2H 2024
- Appointed Eric Dobmeier and Natasha Hernday to the Board of Directors
- Received $7.5 million milestone payment from Merck
- $646.3 million in cash and investments at quarter-end
- Q2 2024 net loss of $6.0 million, compared to $17.5 million in Q2 2023
The company continues to advance its TRACTr and TRACIr platforms for novel cancer immunotherapies.
Janux Therapeutics (Nasdaq: JANX) has announced significant updates to its Board of Directors. Eric Dobmeier and Natasha Hernday have been appointed to the board, bringing extensive operational and business development experience. Eric Dobmeier, former CEO of Chinook Therapeutics, has over 20 years of biotech industry experience. Natasha Hernday, previously Chief Business Officer at Seagen Inc., has a strong track record in strategic partnerships and acquisitions.
Additionally, Jay Lichter, Ph.D., has resigned from the board, and Ronald W. Barrett, Ph.D., a current board member, has been appointed as Chairperson. These changes aim to support Janux's corporate and pipeline strategy as it advances its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms in developing novel immunotherapies for cancer treatment.
FAQ
What is the current stock price of Janux Therapeutics (JANX)?
What is the market cap of Janux Therapeutics (JANX)?
